Intravitreal bevacizumab vs verteporfin photodynamic therapy for neovascular age-related macular degeneration.

@article{Bashshur2007IntravitrealBV,
  title={Intravitreal bevacizumab vs verteporfin photodynamic therapy for neovascular age-related macular degeneration.},
  author={Ziad Fayez Bashshur and Alexandre Raymond Schakal and Rola N. Hamam and Christelle P El Haibi and Rola F. Jaafar and Baha' N Noureddin},
  journal={Archives of ophthalmology},
  year={2007},
  volume={125 10},
  pages={1357-61}
}
OBJECTIVE To compare verteporfin photodynamic therapy (PDT) with intravitreal bevacizumab for management of choroidal neovascularization (CNV) associated with age-related macular degeneration. METHODS Patients with predominantly classic CNV were prospectively randomized to receive standard PDT or intravitreal bevacizumab injections (2.5 mg). Best-corrected visual acuity (BCVA) measured by Snellen charts, central retinal thickness by optical coherence tomography, and greatest linear dimension… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 37 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 47 references

Similar Papers

Loading similar papers…